Enhancement of T-cell activation by the CD43 molecule whose expression is defective in Wiskott-Aldrich syndrome
Por:
Park J.K., Rosenstein Y.J., Remold-O'Donnell E., Bierer B.E., Rosen F.S., Burakoff S.J.
Publicada:
1 ene 1991
Resumen:
CD43 (sialophorin, leukosialin, leukocyte large sialoglyco-protein), a heavily sialylated molecule found on most leukocytes and platelets, was initially identified as a major glycoprotein of mouse, rat and human T cells1-8. CD43 expression is defective on the T cells of males with the Wiskott-Aldrich syndrome, an X chromosome-linked recessive immunodeficiency disorder9. Affected males are susceptible to opportunistic infections and do not respond to polysaccharide antigens, reflecting defects in cytotoxic and helper T-cell functions. Anti-CD43 monoclonal antibodies have a modest costimulatory effect on T cells, natural killer cells, B cells and monocytes10-14, and one such antibody has been shown to activate T cells directly15. To investigate a possible physiological role for CD43, a complementary DNA encoding the human protein16,17 was introduced into an antigen-responsive murine T-cell hybridoma18. We observed that CD43 enhances the antigen-specific activation of T cells and that the intracellular domain of CD43, which is hyperphosphorylated during T-cell activation19-21, is required for this function. We also found that antigen-presenting cells can bind specifically to immobilized purified CD43 and that the binding can be inhibited by liposomes containing CD43 as well as by anti-CD43 monoclonal antibodies. © 1991 Nature Publishing Group.
Filiaciones:
Park J.K.:
Division of Pediatric Oncology, Dana Farber Cancer Institute
Rosenstein Y.J.:
Division of Pediatric Oncology, Dana Farber Cancer Institute
Institute de Investigaciones Biomedicas, UNAM, Mexico, Mexico
Remold-O'Donnell E.:
Center for Blood Research, Harvard Medical School, Boston, MA 02115, United States
Department of Pediatrics, Harvard Medical School, Boston, MA 02115, United States
Bierer B.E.:
Division of Pediatric Oncology, Dana Farber Cancer Institute
Division of Hematology, Brigham and Women's Hospital
Department of Medicine, Harvard Medical School, Boston, MA 02115, United States
Rosen F.S.:
Center for Blood Research, Harvard Medical School, Boston, MA 02115, United States
Department of Pediatrics, Harvard Medical School, Boston, MA 02115, United States
Burakoff S.J.:
Division of Pediatric Oncology, Dana Farber Cancer Institute
Department of Pediatrics, Harvard Medical School, Boston, MA 02115, United States
|